Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine.

Autor:	Folegatti PM; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. pedro.folegatti@ndm.ox.ac.uk., Bellamy D; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. duncan.bellamy@ndm.ox.ac.uk., Roberts R; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. rachel.roberts@ndm.ox.ac.uk., Powlson J; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. jpowlson@gmail.com., Edwards NJ; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. nick.edwards@ndm.ox.ac.uk., Mair CF; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. 2177110M@student.gla.ac.uk., Bowyer G; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. georgina.bowyer@ndm.ox.ac.uk., Poulton I; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. ian.poulton@ndm.ox.ac.uk., Mitton CH; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. celia.mitton@ndm.ox.ac.uk., Green N; Clinical BioManufacturing Facility, Churchill Hospital, University of Oxford, Oxford OX3 7JT, UK. nicky.green@ndm.ox.ac.uk., Berrie E; Clinical BioManufacturing Facility, Churchill Hospital, University of Oxford, Oxford OX3 7JT, UK. eleanor.berrie@ndm.ox.ac.uk., Lawrie AM; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. alison.lawrie@ndm.ox.ac.uk., Hill AVS; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. adrian.hill@ndm.ox.ac.uk., Ewer KJ; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. katie.ewer@ndm.ox.ac.uk., Hermon-Taylor J; Department of Nutritional Sciences, Faculty of Life Sciences & Medicine, Franklin Wilkins Building, King's College London, London SE1 9NH, UK. j.hermon@kcl.ac.uk., Gilbert SC; The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK. sarah.gilbert@ndm.ox.ac.uk.
Jazyk:	angličtina
Zdroj:	Vaccines [Vaccines (Basel)] 2019 May 15; Vol. 7 (2). Date of Electronic Publication: 2019 May 15.
DOI:	10.3390/vaccines7020040
Abstrakt:	Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widespread seroprevalence of neutralising antibodies. We have constructed a replication deficient simian adenovirus-vectored vaccine (ChAdOx2) expressing 4 genes from the Mycobacterium avium subspecies paratuberculosis ( AhpC , Gsd , p12 and mpa ). Safety and T-cell immunogenicity results of the first clinical use of the ChAdOx2 vector are presented here. The trial was conducted using a 'three-plus-three' dose escalation study design. We demonstrate the vaccine is safe, well tolerated and immunogenic. Competing Interests: J.H.-T. is the Chief Scientific and Medical Officer for HAV Vaccines Ltd. S.C.G. and A.V.S.H. are co-founders of, consultants to and shareholders in Vaccitech plc which is developing adenoviral vectored vaccines.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu